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a-Synuclein is an intrinsically disordered protein of 140 amino acids which is abundant in dopami-
nergic neurons. Misfolding and aggregation of a-synuclein leads to the formation of Lewy bodies
inside the neurons which is the hallmark of Parkinson’s disease and related dementias. Here we
show by nanopore analysis that the recreational drug, methamphetamine, binds to the N-terminus
of a-synuclein and causes a conformational change which cannot be detected by circular dichroism
spectroscopy. The results suggest a mechanism for the psychoactivity of methamphetamine as well
as an increased incidence of Parkinson’s disease amongst users of the drug.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Parkinson’s disease (PD) and Lewy body dementia (LBD) are two
of a number of related neurodegenerative diseases which include,
Alzheimer’s disease (AD) Huntington’s disease (HD), the ‘‘prion’’
diseases such as Creutzfeldt–Jakob Disease (CJD), and amyotrophic
lateral sclerosis (ALS) [1]. In all cases, post-mortem analysis of brain
tissue shows the presence of amyloid ﬁbrils, plaques or Lewy bodies
which consist of protein aggregates. Surprisingly, the proteins show
no obvious sequence or structural homology; e.g. a-synuclein in PD
and LBD; Ab, which is derived fromamyloid precursor protein (APP),
in AD; hungtingtin protein inHD; prion protein in CJD; and superox-
idedismutase inALS. The fact that the proteins are not in their native
conformations has led to the hypothesis that they are all ‘‘protein
misfolding diseases’’ [2–4].
In PD and LBD, for example, the ﬁbrils and Lewy bodies are
composed mostly of aggregates of a-synuclein (aS) which has
adopted a b-sheet structure [5–8]. The process of aggregation is
not well understood but presumably occurs through oligomeriza-
tion of the intrinsically disordered protein to form soluble protoﬁ-
brils which then accumulate as insoluble aggregates [9–11]. The
aggregates are found in Lewy bodies, synapses and axons of
dopaminergic neurons, but how this leads to neurodegenerationchemical Societies. Published by E
seaseis not well understood. As is the case with AD, there is good
evidence in PD that the soluble intermediates are the direct cause
of toxicity rather than the aggregates themselves [12–16]. Three
theories have been presented.
First, misfolded proteins are normally sequestered or neutral-
ized by cellular defense mechanisms which include the chaperone,
proteasome and/or autophagosome responses. Thus one patho-
genic possibility is that these responses are affected during PD such
that normal protein turnover, which is essential for cell survival,
cannot function [15,17,18]. A second possibility is based on the
recent observation that aS functions as a ferrireductase which
binds both Cu(II) and Fe(III) to produce Fe(II) with NADH as the
cofactor. The Fe(II) is required by tyrosine hydroxylase to produce
L-DOPA providing a direct link to the survival of dopaminergic neu-
rons [19,20]. As well, Cu(II) and Fe(II) can both produce lethal reac-
tive oxygen species (ROS) so that, again, misfolding of aS could
lead to an increase in these metal ions and cellular toxicity [21].
Third, a very recent paper demonstrates that in vivo, aS exists as
a stably-folded, mostly a-helical tetramer [22]. The authors pro-
pose that the tetramer must be destabilized as a prerequisite to
refolding and aggregation. Whatever the mechanism, the presence
and subsequent misfolding of aS plays a central role.
An emerging technique for studying protein folding and confor-
mation is nanopore analysis [23]. Brieﬂy, nanopores are naturally-
occurring toxins that punch holes in lipid membranes and allow
the passage of small molecules and proteins [24–28]. When a volt-
age is applied across the pore, a currentwill ﬂowwhich is dependentlsevier B.V. All rights reserved.
Fig. 1. Nanopore analysis of the interaction of methamphetamine with full length aS. (a, f) Typical current traces for aS and aS with 20 lM methamphetamine. (b–e)
Blockade current histograms for aS with 0, 5, 10, 20 lM methamphetamine, respectively.
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ever, if a large molecule passes through the pore (called transloca-
tion), or interacts with the pore, but does not pass through (called
a bumping event), the currentwill be reduced. The current blockade(I) and time of blockade (T) represent the ‘‘signature’’ of a single
molecule and can bemeasured by a conventional patch clamp appa-
ratus. When a molecule changes conformation, the values of I and T
will change. After measuring thousands of events, histograms of
Fig. 2. (a) CD spectra for full length aS with and without 10 lM methamphetamine. For comparison the spectrum for myoglobin is also shown. (b–e) Blockade current
histograms for truncated aS(1–60), with 0, 5, 10, 20 lM methamphetamine, respectively.
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averagevaluesof I andT canbederived.Wehaveused this technique
to study the foldingof variouspeptides andproteins [29–32], includ-
ing zinc-ﬁnger proteins in the presence and absence of metal ions
[33], prion-derived peptides in the presence of Cu(II) [34] and Mye-lin Basic Protein in the presence of divalentmetal ions [35]. It is ide-
ally suited for studying peptides such as aS which can adopt
multiple conformations since eachmolecule is interrogated individ-
ually. It is also very sensitive since in theory a singlemolecule can be
detected. Therefore, nanopore experiments can be performed at
Fig. 3. (a, b) Blockade current histograms for aS(DNAC) with 0 lM and 10 lM methamphetamine. (c, d) Blockade current histograms for aS(61–140) with 0 lM and 10 lM
methamphetamine.
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at all. Thus there are several advantages compared to conventional
structural techniques such as NMR or X-ray crystallography [23].
Several studies suggest that environmental factors are impor-
tant for the development of Parkinson’s disease. For example, Para-
quat is common pesticide that has been implicated as a potential
neurotoxicant in PD [36]. Similarly, it is known that the psychoac-
tive effects of methamphetamine are caused by dopamine release
and recently it has been reported that methamphetamine addicts
have a higher incidence of PD [37,38]. Furthermore, overexpression
of aS within neurons of the substantia nigra induced by amphet-
amine derivatives is related to the occurrence of intracellular inclu-
sions [39,40]. Here we demonstrate by nanopore analysis that
methamphetamine causes a conformational change in aS. It is
known that a-synuclein binds dopamine and we propose that
methamphetamine binds to the protein and causes release of
dopamine. If this proves to be correct then there is a direct link
not only between methamphetamine and its psychoactivity but
also between methamphetamine abuse and the increased inci-
dence of PD.
2. Materials and methods
a-Synuclein and the truncated peptides were purchased from
rPeptide (Bogart, GA, USA). Theywere dissolved in water at concen-
tration of 1 mg/ml. (+)-Methamphetamine hydrochloride solutionat 1 mg/ml, analytical standard for drug analysis, was purchased
from Sigma–Aldrich.
Nanopore analysis of these isoforms in a buffer of 1 M KCl,
10 mM HEPES–KOH, pH 7.8 was performed as described in detail
previously [23,33,34]. Brieﬂy, a lipid bilayer was painted onto a
150 lM aperture in a teﬂon perfusion cup which separated two
buffer compartments of volume 1.5 mL. a-Hemolysin was pur-
chased from Sigma–Aldrich and diluted in buffer to a ﬁnal concen-
tration of 1 lg/mL. 5 lL of this solution was added to one side of
the membrane and stable pore insertion was conﬁrmed by an in-
crease in the current to 100 pA. The protein (6 lL, 14.5 lL, 8.5 lL
and 12 lL of aS (1–60), aS, aS (61–140) and aS (DNAC) peptide
solutions of 1 mg/mL, respectively) was added to the cis-side of
the pore with the positive electrode on the trans-side. The ﬁnal
concentration of protein at the cis-side was 1 lM. The experiments
were carried out at 22 ± 1 C with an applied potential of 100 mV
at a band width of 10 kHz using an Axopatch 200B ampliﬁer (Axon
Instruments) under voltage clamp conditions. The blockade cur-
rent populations were obtained by ﬁtting the blockade current dis-
tribution with the Gaussian function [23,33,34].
The circular dichroism (CD) spectra of aS were recorded on an
Applied Photophysics p⁄-180 spectrophotometer at 22 ± 1 C. Pep-
tide solutions used for the CD measurements were made in 10 mM
potassiumphosphate buffer at pH7.8 at 0.5 mg/ml. The spectropho-
tometer was calibrated with a solution of (1S)-(+)-10-camphorsul-
fonic acid. Corrections to the record spectra were made by
Fig. 4. (a) Proposed binding site for methamphetamine in the N-terminal region of aS. (b) Full length aS can readily translocate the a-hemolysin pore from the C-terminal
end which carries a net negative charge. In the presence of methamphetamine, a loop is formed which causes bumping events to be more likely.
3226 O. Tavassoly, J.S. Lee / FEBS Letters 586 (2012) 3222–3228subtracting the spectrum of the buffer or the spectrum of the buffer
and the ligand. The mean residue ellipticity (hMRE) is calculated to
normalize the ellipticity. Themean residue ellipticity (hMRE) was re-
ported in deg cm2 dmol1 [41]. In order to allow for the comparisons
between the CD spectra of aSwith a typical spectrum of a-helix, the
CD spectrum of horse myoglobin (PCDDBID: CD0000047000) was
used [42,43]. The unit of myoglobin spectra, delta epsilon, was
converted to the mean residue ellipticity [41].
The 3D structure of aS (PDB ID: 1XQ8) together with the proton-
ated form of the 3D conformer of (+)-methamphetamine (PubChem
CID: 10836) were used for the docking simulation which was per-
formed using molecular operating environment (MOE) from the
Chemical Computing Group, Inc. as described previously [44].
Brieﬂy, the target peptide, aS(1–60), was subjected to an MMFF94
energy minimization protocol until the root mean square of the
conjugate gradient reached <0.05 kcal mol1 Å1. The MOE-Dock
default parameters were used for the docking simulation. The
MMFF94s was selected as the force ﬁeld [44]. Reﬁnement and
Rescoring 2 were set up to the Forceﬁeld and Alpha HB, respec-
tively. A global docking was performed with the target peptide.
The docking was carried out for 30 iterations. The docking interac-
tion with the lowest energy (50 kcal/mol) is shown in Fig. 4a.
3. Results and discussion
A typical current trace for aS covering about 6s is shown in
Fig. 1a and most of the events have large current blockades. Aftercollecting events for about 30 min a current blockade histogram
can be derived which is shown in Fig. 1b. The major peak is at
85 pA and, as discussed previously, this is due to translocation
of the protein since the time of the events decreases with increas-
ing applied voltage [23]. The minor peak at 25 pA is due to bump-
ing events which represent about 9% of the total number of events.
The effect of increasing methamphetamine concentrations are
shown in Fig. 1c–e. At 5 lM the translocation peak is decreased
and the % events in the bumping peak increases to 34%. There
are also a large number of events with intermediate current block-
ades which are difﬁcult to characterize because they do not yield a
clear Gaussian distribution. At 10 lM of drug the bumping events
increase to about 43% and at 20 lM, there is a further increase to
50%. A typical current trace for 20 lM drug is shown in Fig. 1f
which clearly shows a decrease in the proportion of translocation
events compared to Fig. 1a. In these experiments, the concentra-
tion of aS is 1 lM so that the binding constant (Ka) is in the range
of 105–106 M1. It would appear that the drug/aS complex can give
rise to some translocation events because they are still observed
even at the highest drug concentration. As well, because of the
presence of intermediate peaks it is not possible to calculate a
more accurate value for Ka.
In general, an increase in bumping events can be attributed to
the folding of a molecule into a more compact conformation which
impedes translocation. For example, addition of Zn2+ to a Zn-ﬁnger
peptide causes formation of a compact b-sheet/a-helix sandwich
which can no longer translocate [33]. As expected, the transition
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by a large change in the CD spectrum [45]. As shown in Fig. 2a, the
CD spectrum of aS is very weak and typical of an intrinsically dis-
ordered protein compared to myoglobin, for example, which is
mostly a-helical. However, addition of methamphetamine does
not cause a signiﬁcant change in the CD spectrum of aS which
implies that the drug is not inducing an a-helical or b-sheet confor-
mation. On the other hand, formation of a simple loop or binding
pocket (see Fig. 4) would not be expected to alter the CD spectrum
but would effect the event proﬁle; a result which emphasizes that
nanopore analysis can detect subtle conformational changes which
may not be amenable to spectroscopic techniques.
The aS protein can be divided into three regions; the N-terminus
comprising amino acids 1–60 which can adopt an a-helical confor-
mation when bound to anionic lipids; a central hydrophobic NAC
domain (61–95) which is thought to be responsible for b-sheet for-
mation and eventual ﬁbrillization; and an acidic C-terminus which
contains the binding site for dopamine [46,47]. In order to delineate
the binding site of methamphetamine, several deletion mutants
were studied. Fig. 2b–e shows the results for the N-terminal peptide
aS(1–60). In the absence of drug (Fig. 2b) there is no clear transloca-
tion peak and about 73% of the events are bumpings. Upon addition
of increasing concentrations of drug the proportion of bumping
events decreases to 51%, 30%, and 23% in the presence of 5, 10 and
20 lM drug, respectively. Simultaneously, there is an increase in
the proportion of events with higher blockade current and at
20 lM drug about 15% of the events have blockade currents above
80 pA, presumably due to translocations. From these results it is
clear that methamphetamine binds to the N-terminus and causes
a conformational change although it is not obvious why there are
fewer bumping events in the presence of the drug in the case of
aS(1–60) but more bumping events for the full length protein. One
explanation is that the truncated peptide has a net charge of +4
whereas the full-length protein has a net charge of 9 (because
the C-terminus is acidic). Therefore, aS(1–140) will be electropho-
retically driven towards the pore whereas the interaction of aS(1–
60) with the pore will be diffusion controlled. Moreover, it has been
demonstrated previously that the dipole moment of a peptide can
have a profound effect on the ratio of translocation to bumping
events [32,48]. aS(1–140) has a large dipole moment because of
the preponderance of negative charge on the C-terminus which will
position the protein on the correct trajectory for translocation i.e. C-
terminus toward the pore (see Fig. 4b). In contrast, inspection of the
sequence of aS(1–60) shows that it will have a much smaller dipole
moment because the charge is evenly distributed. Thus, in an un-
folded state it is likely to straddle the pore giving rise to a typical
bumping event.
An N-terminal binding site for methamphetamine was conﬁrmed
by investigating aS(DNAC) (Fig. 3a and b) for which there is an
increase in bumping events on addition of drug and aS(61–140)
(Fig. 3c and d) forwhich the drug has no apparent effect on the block-
ade current proﬁle. A possible binding site in the N-terminus encom-
passing residues 35–44 (Fig. 4a) was identiﬁed by docking
methamphetamine to unfolded aS(1–60) using molecular operating
environment (MOE) from the Chemical Computing Group, Inc. [44].
The binding is stabilized in part by polar interactions between
Glu35, Gly36, Tyr39 and Thr44, and the amine of the drug as well
van der Waals interactions between Leu38, Val40 and Lys43 and
the benzene ring of the drug. The peptide becomes folded around
the drug forming a loop which is stabilized by ionic interaction
between Glu35 and Lys43 (Fig. 4a). In order for the complex to trans-
locate the loop would presumably have to unfold and so bumping
events become more prevalent.
In conclusion, we have shown that methamphetamine binds aS
in the N-terminal region causing a conformational change which
can be detected by nanopore analysis but not CD. The interactionmay be responsible for the psychoactivity of methamphetamine
as well as the increased incidence of PD amongst drug users. In
the long term, this technique will prove useful for assessing candi-
date drugs for treating PD.References
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